(Circulation. 2001;104:1881.)
© 2001 American Heart Association, Inc.
Editorial |
Cholesterol in Vascular and Valvular Calcification
From the Departments of Medicine and Physiology, UCLA School of Medicine, Los Angeles, Calif.
Correspondence to Linda L. Demer, MD, PhD, Maud Cady Guthman Professor of Medicine and Physiology, Vice Chair, Department of Medicine, UCLA School of Medicine, Mail Box 951679, Los Angeles, CA 90095-1679.
Key Words: Editorials • atherosclerosis • calcium • lipids
In the early 1990s, the late Jeff Hoeg had the foresight to ask whether vascular calcification relates to the duration and severity of exposure to cholesterol. In a group of homozygous hyperlipidemic patients for whom detailed records of cholesterol levels were available over a long period of time, he and his colleagues found that coronary calcification scores by ultrafast computed tomographic scanning correlated significantly with the cholesterol year product.1 Studies that lack long-term cholesterol history may miss a correlation between lipids and calcification, because current treatments so dramatically change cholesterol levels as to make them unrepresentative of long-term exposure.
See p 1927
In the present issue of Circulation, Pohle et al2 successfully overcame these difficulties by studying the rate of change in calcification as a function of change in lipid levels, excluding patients in whom treatment was altered during the study period. These investigators found that both coronary calcification and aortic valve calcification progress more rapidly in subjects with levels of LDL >130 mg/dL. This finding dovetails with those of Callister et al,3 who discovered that patients who successfully lowered their cholesterol levels with lipid-lowering agents significantly reduced the progression of coronary calcification. In a large population of young subjects, the risk factor that correlated most significantly with coronary calcification was LDL cholesterol.4 This relation was stronger than the correlation with age, smoking, fasting insulin, blood pressure, or male sex.4 In another study of asymptomatic outpatients, LDL cholesterol was the only risk factor correlating with progression of coronary calcification
This article has been cited by other articles:
 |
|
 |
|
  N. M. Rajamannan Mechanisms of aortic valve calcification: the LDL-density-radius theory: a translation from cell signaling to physiology Am J Physiol Heart Circ Physiol, January 1, 2010; 298(1): H5 - H15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Rajamannan Calcific Aortic Stenosis: Lessons Learned From Experimental and Clinical Studies Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 162 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zeng, P. Nievelstein-Post, Y. Yin, K.-M. Jan, J. S. Frank, and D. S. Rumschitzki Macromolecular transport in heart valves. III. Experiment and theory for the size distribution of extracellular liposomes in hyperlipidemic rabbits Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2687 - H2697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Arishiro, M. Hoshiga, N. Negoro, D. Jin, S. Takai, M. Miyazaki, T. Ishihara, and T. Hanafusa Angiotensin Receptor-1 Blocker Inhibits Atherosclerotic Changes and Endothelial Disruption of the Aortic Valve in Hypercholesterolemic Rabbits J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1482 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Aikawa, M. Nahrendorf, D. Sosnovik, V. M. Lok, F. A. Jaffer, M. Aikawa, and R. Weissleder Multimodality Molecular Imaging Identifies Proteolytic and Osteogenic Activities in Early Aortic Valve Disease Circulation, January 23, 2007; 115(3): 377 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Aboulhosn and J. S. Child Left Ventricular Outflow Obstruction: Subaortic Stenosis, Bicuspid Aortic Valve, Supravalvar Aortic Stenosis, and Coarctation of the Aorta Circulation, November 28, 2006; 114(22): 2412 - 2422. [Full Text] [PDF]
|
|
|
|
|
|
B. Wu, S. Elmariah, F. S. Kaplan, G. Cheng, and E. R. Mohler III Paradoxical Effects of Statins on Aortic Valve Myofibroblasts and Osteoblasts: Implications for End-Stage Valvular Heart Disease Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 592 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Farivar, L. H. Cohn, E. G. Soltesz, T. Mihaljevic, J. D. Rawn, and J. G. Byrne Transcriptional profiling and growth kinetics of endothelium reveals differences between cells derived from porcine aorta versus aortic valve Eur. J. Cardiothorac. Surg., October 1, 2003; 24(4): 527 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Farivar and L. H. Cohn Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 969 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Bashore and T. J. Gardner Valvular heart disease J. Am. Coll. Cardiol., July 16, 2003; 42(2): 388 - 390. [Full Text] [PDF]
|
|
|
|
 |
|
 S Atar, D S Jeon, H Luo, and R J Siegel Mitral annular calcification: a marker of severe coronary artery disease in patients under 65 years old Heart, February 1, 2003; 89(2): 161 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bidder, J.-S. Shao, N. Charlton-Kachigian, A. P. Loewy, C. F. Semenkovich, and D. A. Towler Osteopontin Transcription in Aortic Vascular Smooth Muscle Cells Is Controlled by Glucose-regulated Upstream Stimulatory Factor and Activator Protein-1 Activities J. Biol. Chem., November 8, 2002; 277(46): 44485 - 44496. [Abstract] [Full Text] [PDF]
|
|